Roche’s latest Nvidia build is not just another AI headline. It is a sign that in biotech, the next real advantage may come from owning the compute, data and workflows needed to use AI at industrial scale.
When Roche said this week that it was adding 2,176 Nvidia Blackwell GPUs across sites in the United States and Europe, the easy story was scale. The more important story was intent. Roche said its combined cloud and on-premise Blackwell footprint now exceeds 3,500 GPUs and will be used across the value chain, from discovery and clinical development to manufacturing,
